CytRx, a biopharm research and development company specializing in oncology, was recently covered in an article by SeekingAlpha contributor John Mylant who discusses recent data that demonstrates the potential of CytRx’ aldoxorubicin as a substitute for commonly used doxorubicin. Mylant is the founder and CEO for OptionsWeekly.org and a long-time trading coach.
To read the entire article visit http://seekingalpha.com/article/1848951
Aldoxorubicin is an improved formulation of doxorubicin, a widely used chemotherapy drug. CytRx recently released interim clinical data from a phase 2b trial in which aldoxorubicin was compared to doxorubicin for the first-line treatment of soft tissue sarcomas (STS).
To summarize, results show that patients administered aldoxorubicin were able to tolerate 3.5 times the standard dose of doxorubicin with fewer side effects, resulting in greater positive response to treatment.
“The recent results from the phase 2b trial reinforces the possibility that aldoxorubicin could one day replace doxorubicin,” writes Mylant.
He also notes that at the end of September, CytRx was debt-free with approximately $23 million in short-term investments and cash equivalents.
“As with most companies in the biotech field, when the company is in research and has not yet brought a “product to the market,” it relies on raising investment capital continue to operate. I am encouraged by the interim clinical trial results to date and am optimistic for the additional phase 2b trial data which the company expects to report in December. As the company gets closer to FDA approval of aldoxorubicin, I would expect to see the share price increase in value as most biotech companies do,” said Mylant in conclusion.
For more information, visit www.cytrx.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment